Lineage Cell Therapeutics Inc.
03/11/2026 | Press release | Distributed by Public on 03/11/2026 07:00
Material Event (Form 8-K)
Item 8.01 Other Events.
On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement dated March 11, 2026 (the "Prospectus Supplement") to the prospectus dated May 14, 2024 (the "Base Prospectus") that forms a part of the Company's shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the SEC on March 7, 2024 and declared effective by the SEC on May 14, 2024 (the "Registration Statement"), as supplemented, modified and superseded by the prospectus supplements dated November 12, 2025 and May 14, 2024 (the "Prior Supplements"), relating to the offer and sale of the Company's common shares from time to time through or to B. Riley Securities, Inc. ("B. Riley"), pursuant to the sales agreement the Company entered into with B. Riley dated March 22, 2024 (the "Sales Agreement").
The Prospectus Supplement relates to the offer and sale of the Company's common shares under the Sales Agreement having an aggregate offering price of up to $60,000,000 (the "ATM Shares"), excluding the $22,583,663.82 in aggregate gross sales price of the Company's common shares sold pursuant to the Prior Supplements and Base Prospectus to date. The ATM Shares are being offered and sold pursuant to the Registration Statement, the Base Prospectus, the Prior Supplements and the Prospectus Supplement.
This report shall not constitute an offer to sell or the solicitation of an offer to buy the ATM Shares, nor shall there be any sale of the ATM Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A copy of the opinion of Sheppard, Mullin, Richter & Hampton LLP relating to the legality of the ATM Shares covered by the Prospectus Supplement is attached hereto as Exhibit 5.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
|
5.1 |
Opinion of Sheppard, Mullin, Richter & Hampton LLP |
|
|
23.1 |
Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1) |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Lineage Cell Therapeutics Inc. published this content on March 11, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 11, 2026 at 13:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]